Skip to main content
. Author manuscript; available in PMC: 2019 Sep 5.
Published in final edited form as: Leukemia. 2019 Mar 12;33(9):2208–2226. doi: 10.1038/s41375-019-0414-z

Figure 5. Key antigen expression and functional activities of specific Tetramer+ hBCMA72–80 CTL against MM cells.

Figure 5

Figure 5

Figure 5

Heteroclitic hBCMA72–80 CTL were evaluated for phenotype and anti-MM activities related to Tetramer-positivity. Fig. 5A. Representative flow analyses of key activation (CD38) and costimulatory (CD40L, 41BB, OX40, GITR) molecules expression in hBCMA72–80 peptide specific Tetramer-positive or Tetramer-negative CTL subset. Fig. 5B. Flow cytometry analyses of functional CD107a degranulation by Tetramer-positive or Tetramer-negative cells in hBCMA72–80 CTL (Donor A, Donor B, Donor C; N=3) against HLA-A2+ U266 MM cells. Fig. 5C. Flow cytometry analyses of Tetramer-positivity within the functional CD107a+ hBCMA72–80 CTL (Donor A, Donor B, Donor C; N=3) in response to HLA-A2+ U266 MM cells.